异基因外周血造血干细胞移植治疗骨髓增生异常综合征23例疗效分析  

Effectiveness analysis of allogeneic peripheral blood stem cell transplantation in 23 patients with myelodysplastic syndromes

作　　者：胡亮钉[1] 陈虎[1] 江岷[1] 李渤涛[1] 秦茂权[1] 俞志勇[1] 李欲航[1] 

机构地区：[1]军事医学科学院附属医院全军造血干细胞移植中心,北京100710

出　　处：《中华血液学杂志》2006年第8期522-524,共3页Chinese Journal of Hematology

摘　　要：目的观察异基因外周血造血干细胞移植(allo-PBSCT)治疗骨髓增生异常综合征(MDS)的疗效。方法对23例 MDS 患者行 HLA 相合的同胞间 allo-PBSCT,供者外周血采集前给予G-CSF 动员。输注外周血单个核细胞8.25(4.50～22.36)×10~8/kg,CD34^+细胞5.59(1.57～12.22)×lO^6/kg 移植物抗宿主病(GVHD)的预防给予环孢菌素 A 加短疗程甲氨蝶呤,移植后1天(+1天)～+28天给予霉酚酸酯。结果 23例患者中22例造血完全重建。中性粒细胞>1.0×10~9/L 和 BPC>50 × 10~9/L 的时间分别为+13(+11～+17)天和+30(+13～+102)天。移植相关死亡2例,移植后复发3例,现18例存活。 Kaplan-Meier 分析显示无病生存率、复发率分别为(77.8±8.7)%和(14.4±7.5)%。结论 Allo-PBSCT 治疗 MDS 治愈率高,复发率低。Objective To analyse the outcome of allogeneic peripheral blood stern cell transplantation （allo-PBSCT） for myelodysplastie syndromes （MDS）. Methods Twenty-three patients with MDS received G-CSF mobilized HLA-identical sibling allo-PBSCT. The numbers of mononuelear cells （MNC） and CD34 ＋ cells were 8.25 （4.50-22.36）×10^8/kg and 5.59 （ 1.57-12.22） × 10^6/kg respectively. CsA and shorten course MTX were used for graft-versus-host disease（GVHD） prophylaxis and MMF was given on ＋ 1 d-＋28d posttransplantation. Results Among 23 patients, 22 achieved hematopoietic recovery. The median time ofANC 〉1.0×10^9g/Land BPC〉 50×10^9/L were ＋13（ ＋11-＋17） days and ＋30（ ＋13 - ＋ 102） days respectively. Two patients died of transplant related complications and three died of disease relapse, while 18 patients survived. Kaplan-Meier analysis showed disease free survival and relapse rate were （77.8±8.7）% and （14.4 ±7.5）% respectively. Conclusion Allo-PBSCT is an effective treatment for MDS patients.

关 键 词：造血于细胞移植 骨髓增生异常综合征 

分 类 号：R55[医药卫生—血液循环系统疾病]